文献速递免疫规划

异源AZD1222初免和BNT162b2加强方案较同源BNT162b2方案更有效诱导中和抗体,但不增强记忆T细胞

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
PubMed 文献 · Vaccine · 2023-02-06

这项前瞻性观察性队列研究比较了同源BNT162b2/BNT162b2、同源AZD1222/AZD1222、异源AZD1222/BNT162b2以及既往野生型SARS-CoV-2感染/接种组中针对刺突蛋白的IgG、中和抗体和T细胞反应。结果显示异源AZD1222/BNT162b2组和感染/接种组的中和抗体峰值滴度显著高于同源BNT162b2或AZD1222组,但同源BNT162b2组的干扰素-γ产生CD4+ T细胞频率最高。针对Delta变异株,感染/接种组的中和抗体和CD4+ T细胞反应高于其他同源或异源接种方案组。

要点

  • 异源AZD1222/BNT162b2组和既往感染/接种组的中和抗体峰值滴度显著高于同源BNT162b2或AZD1222组。
  • 同源BNT162b2组的干扰素-γ产生CD4+ T细胞频率最高,多能T细胞分析结果类似。
  • 针对Delta变异株,既往感染/接种组的中和抗体和CD4+ T细胞反应高于其他同源或异源接种方案组。

核心结论

  • 异源AZD1222/BNT162b2接种和既往感染/接种能有效诱导中和抗体,而同源BNT162b2接种能有效诱导刺突特异性CD4+ T细胞反应。
  • 既往感染/接种比其他同源或异源接种方案更有效地产生识别变异株的免疫。

研究设计与样本

  • 前瞻性观察性队列研究,评估年龄匹配的同源BNT162b2/BNT162b2、同源AZD1222/AZD1222、异源AZD1222/BNT162b2接种组及既往野生型SARS-CoV-2感染/接种组的刺突特异性IgG、中和抗体和T细胞反应。

主要发现

  • 未接种组中,峰值免疫反应在第二剂疫苗后达到;既往感染/接种组中,峰值免疫反应在第一剂后达到。
  • 抗刺突IgG和中和抗体峰值滴度在AZD1222/BNT162b2组和既往感染/接种组显著高于BNT162b2/BNT162b2组或AZD1222/AZD1222组。
  • 干扰素-γ产生CD4+ T细胞频率在BNT162b2/BNT162b2组最高,多能T细胞分析结果类似。
  • 针对Delta变异株,既往感染/接种组的中和抗体和CD4+ T细胞反应高于其他同源或异源接种方案组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Comparative analyses of SARS-CoV-2-specific immune responses elicited by diverse prime-boost regimens are required to establish efficient regimens for the control of COVID-19. METHOD: In this prospective observational cohort study, spike-specific immunoglobulin G (IgG) and neutralizing antibodies (nAbs) alongside spike-specific T-cell responses in age-matched groups of homologous BNT162b2/BNT162b2 or AZD1222/AZD1222 vaccination, heterologous AZD1222/BNT162b2 vaccination, and prior wild-type SARS-CoV-2 infection/vaccination were evaluated. RESULTS: Peak immune responses were achieved after the second vaccine dose in the naïve vaccinated groups and after the first dose in the prior infection/vaccination group. Peak titers of anti-spike IgG and nAb were significantly higher in the AZD1222/BNT162b2 vaccination and prior infection/vaccination groups than in the BNT162b2/BNT162b2 or AZD1222/AZD1222 groups. However, the frequency of interferon-γ-producing CD4+ T cells was highest in the BNT162b2/BNT162b2 vaccination group. Similar results were observed in the analysis of polyfunctional T cells. When nAb and CD4+T-cell responses against the Delta variant were analyzed, the prior infection/vaccination group exhibited higher responses than the groups of other homologous or heterologous vaccination regimens. CONCLUSION: nAbs are efficiently elicited by heterologous AZD1222/BNT162b2 vaccination, as well as prior infection/vaccination, whereas spike-specific CD4+T-cell responses are efficiently elicited by homologous BNT162b2 vaccination. Variant-recognizing immunity is more efficiently generated by prior infection/vaccination than the other homologous or heterologous vaccination regimens.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Baek YJ, Kim WJ, Ko JH, et al. A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen. Vaccine. 2023. PMID: 36754764. doi:10.1016/j.vaccine.2023.01.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。